Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent~* General good health~* Diagnosis of asthma as defined by the National Institutes of Health (NIH)~* A best FEV1 of 40%-85% of the predicted normal value during the screening visit (SV)~* Subjects need to demonstrate a ≥ 15% reversibility of FEV1 within 30 minutes following 4 inhalations of albuterol inhalation aerosol (if required, spacers are permitted for reversibility testing) at the SV.~* Other inclusion criteria apply~Exclusion Criteria:~* History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.~* Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks prior to the SV.~* Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV.~* Taking long-acting β-agonists within 2 weeks of the SV~* Other exclusion criteria apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FS MDPI 100/6.25 mcg (Type: EXPERIMENTAL): Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.
- FS MDPI 100/12.5mcg (Type: EXPERIMENTAL): Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.
- FS MDPI 100/25 (Type: EXPERIMENTAL): Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.
- FS MDPI 100/50 (Type: EXPERIMENTAL): Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.
- Fp MDPI 100 mcg (Type: ACTIVE_COMPARATOR): Subjects inhaled a single dose of 100 mcg fluticasone propionate.
- Advair Diskus 100/50 mcg (Type: ACTIVE_COMPARATOR): Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.

Based on this trial design, predict the completion outcome and termination type (if applicable).